Risedronate Sodium  Tablets

35 & 150 mg



Risedronate belongs to the therapeutic group of bisphosphonates which slow bone loss. The product is indicated for treatment and prevention of osteoporosis.
Unipharm’s generic Risedronate Tablets have been manufactured and marketed in Israel since 2011.
In Israel, most patients have switched from the once-weekly Risedronate 35 mg strength to the once-monthly Risedronate 150 mg strength, enabling better compliance and adherence to the treatment.

  • ATC4: M05BA
  • Strengths: 35 & 150 mg
  • Dosage forms: Tablets
  • Out-licensing is offered for all international markets*
  • Zone IVb stability data is available
* Product availability is subject to patent restrictions in countries where applicable patents are in effect

related products